TransCode Therapeutics (NASDAQ:RNAZ) Issues Quarterly Earnings Results

TransCode Therapeutics (NASDAQ:RNAZ) issued its earnings results on Friday. The company reported ($7.17) earnings per share (EPS) for the quarter, FiscalAI reports.

TransCode Therapeutics Stock Performance

RNAZ stock opened at $3.28 on Friday. TransCode Therapeutics has a one year low of $3.21 and a one year high of $20.99. The firm has a market cap of $3.47 million, a PE ratio of -0.06 and a beta of 1.24. The firm’s 50 day moving average price is $6.00 and its 200-day moving average price is $7.64.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TransCode Therapeutics in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.